The purinergic system in allotransplantation.

Area of Science:

• Immunology
• Biochemistry
• Transplantation Science

Background:

• Adenosine triphosphate (ATP) is a key intracellular energy source, but also acts as an extracellular signaling molecule.
• Extracellular ATP (eATP) and its metabolites bind to purinergic receptors (P2X, P2Y, P1) on immune cells, modulating immune functions like proliferation and cytokine release.
• The purinergic system plays a critical role in immune cell activation and regulation.

Purpose of the Study:

• To review the role of the purinergic system in immune responses, particularly in the context of transplantation.
• To explore the therapeutic potential of targeting purinergic signaling pathways, specifically the eATP/P2X7R axis, for improving allograft outcomes.
• To highlight novel P2X receptor inhibitors as potential immunomodulatory agents in transplantation.

Main Methods:

• Literature review focusing on the purinergic system's involvement in immune cell function and transplantation.
• Analysis of studies investigating the eATP/P2X7R axis in murine models of transplantation.
• Examination of current and emerging P2X receptor inhibitors for immunomodulatory applications.

Main Results:

• Extracellular ATP (eATP) binding to P2X and P2Y receptors mediates immune cell activation, while adenosine binding to P1 receptors generally inhibits immune responses.
• The eATP/P2X7R axis is significantly implicated in allograft rejection and graft-versus-host disease (GVHD) severity.
• Targeting the eATP/P2X7R pathway in murine models demonstrated improved long-term graft function and reduced GVHD.

Conclusions:

• The purinergic system, particularly eATP signaling, is a critical regulator of immune responses relevant to transplantation.
• Targeting the eATP/P2X7R axis represents a promising therapeutic strategy to mitigate allograft rejection and GVHD.
• Available P2X receptor inhibitors offer potential for novel immunomodulatory treatments in transplant patients.